Press Releases
June 1, 2022
Costco Wholesale Corporation Adds Nerivio® to Its Member Prescription Program
Nerivio is the First Migraine Treatment Device Offered to Costco Prescription Program Members
Read More
February 16, 2022
Peer-Reviewed Study Shows Positive Impact of Nerivio’s® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response
Analysis Examined Nerivio’s Remote Electrical Neuromodulation (REN) Migraine Treatment Augmented with its New In-App GIER Feature
Jan 19, 2022
Large Real-World Evidence Analysis Provides Comprehensive Evaluation of Nerivio® as an Effective Acute Treatment for Migraine
Largest peer-reviewed real-world study of a migraine device demonstrates that remote electrical neuromodulation (REN) provides a safe and effective drug-free acute treatment option for migraine sufferers
December 15, 2021
Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors
Former President and CEO of the Blue Cross Blue Shield Association, Serota Brings Decades of Experience in US Healthcare Leadership
October18, 2021
Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine
Study shows remote electrical neuromodulation (REN) treatment provides relief for migraine headaches, offering a drug-free acute treatment option for people with chronic migraine
October 4, 2021
MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica’s Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic
Agreement Simplifies and Accelerates Patient Access to Effective, Low Side Effect Drug Free Therapy for Acute Treatment of Migraine
August 15, 2021
Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)
Granting of the Code Follows Continued Successful Clinical Trials of Nerivio in Adolescent Patients as well as those with Menstrual Migraine
June 30, 2021
Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents
Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation
June 21, 2021
Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache
20%-25% of women with migraine have menstrual migraine, which is typically associated with greater disability
March 2, 2021
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents
February 16, 2021
Veterans Affairs (VA) Signs Agreement with Theranica to Make Nerivio® Acute Migraine Therapeutic Device Available to Veterans
Drug-Free Smartphone-Controlled Wearable Device Will Address Veteran Community, which has Higher Prevalence Migraine Compared to the General Population
January 25, 2021
FDA Approves Theranica’s Nerivio® for Acute Treatment of Migraine in Adolescents
The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above
October 26, 2020
Nerivio® Receives Clearance of Expanded Indication to Cover Chronic Migraine Patients
Clinical Evidence Supports Efficacy of Theranica’s Prescribed Digital Therapeutic in Adult Chronic Migraine Patients
September 17, 2020
Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica’s Nerivio® Device Copy
Peer-Reviewed Post-Marketing Surveillance Study Tested Efficacy and Safety of Remote Electrical Neuromodulation (REN) in Acute Treatment of Migraine
September 8, 2020
Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe
Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021
Read More
July 16, 2020
KRAIBURG TPE supplies custom-colored medical-grade thermoplastic elastomer for Nerivio, an innovative drug-free neuromodulation therapeutic wearable from Theranica
Nerivio®, a novel wireless neuromodulation wearable from Theranica for drug-free acute treatment of migraine, features an electronic housing molded in a THERMOLAST® M custom-colored medical-grade thermoplastic elastomer compound from KRAIBURG TPE.
Read More
July 15, 2020
Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients
New Peer-Reviewed Article Publishes Results of Clinical Study Testing Efficacy of Remote Electrical Neuromodulation in Acute Treatment of Migraine in Chronic Migraine Patients
June 1, 2020
Theranica Kicks Off Migraine Awareness Month Rebate Program for Nerivio®, Its FDA-Authorized Migraine Treatment Wearable
Amid COVID-19, Patients Report Greater Incidence of Stress-Related Migraines
Read More
May 18, 2020
Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device
During Initial Limited Commercial Launch, Nerivio® Was Used more than 30,000 Times to Address Migraine Pain and other Symptoms
April 6, 2020
Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform
FDA-Authorized Drug-Free Migraine Treatment Device Available by Prescription through One-Stop Telemedicine Platform
March 10, 2020
Theranica Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine, Recognized as a Leading Biotech Innovator
February 25, 2020
Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove
Cove Provides Rapid Consultation with a Licensed Physician and Home Delivery of the Novel FDA-Authorized Prescribed Wearable Device
December 18, 2019
Theranica Named 2020 ‘Game Changer’ by CB Insights
BioMed Tech Developer Included in “Electro-Charged Therapeutics” Category Recognizing Companies Creating a Drug-Free Future
December 3, 2019
Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio
Review Highlights Efficacy and Safety of Smartphone-Controlled Prescribed Wearable for the Acute Treatment of Migraine
November 21, 2019
Theranica’s Nerivio™ Named in TIME’s List of 100 Best Inventions of 2019
Acute Migraine Smartphone-Controlled Prescription Wearable Recognized in Health Care Category
November 18, 2019
Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production
Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable
July 23, 2019
New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Headache Researchers in California and Missouri Conducted a Per-Patient Comparison of FDA-Cleared Wearable Device with Contemporary Usual Care
June 24, 2019
Theranica Appoints Senior Executives to Lead its New USA Subsidiary
New Executive Team Will Oversee US Commercialization of FDA-Cleared Nerivio™ for Acute Treatment of Migraine
May 28, 2019
FDA Grants Theranica De Novo to Market First Smartphone-Controlled Acute Migraine-Relief Wearable Device
Clinical Data Show 66.7% Pain Relief Response Within Two Hours
May 13, 2019
OMRON VENTURES Joins Theranica’s Series B Funding Round as Strategic Investor
Strategic investment signals positive response of healthcare community to Theranica’s new approach to migraine management
March 18, 2019
Theranica Raises $35M to Bring Innovative Migraine Device to the USA aMoon leads round B of financing of the Israel-based company
aMoon leads round B of financing of the Israel-based company
November 15, 2018
Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine
Results of largest study with a migraine device solidify safety, efficacy and tolerability of the drug-free Nerivio Migra, offering huge clinical benefit for migraineurs
July 03, 2017
Theranica Raises $6M to Combat Migraine
Lightspeed leads round A of financing in Israel-based advanced e-health company
